INBRX-101
- Generic Name
- INBRX-101
- Drug Type
- Biotech
- Background
INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein.
Novel Therapies Poised to Revolutionize Alpha-1 Antitrypsin Deficiency Treatment
• Current AATD treatment, augmentation therapy, involves weekly infusions but doesn't reverse lung or liver damage, spurring the development of novel therapies.
• Fazirsiran, an RNAi therapy by Arrowhead and Takeda, shows promise in reducing Z-AAT levels in Phase II trials, with Phase III trials underway for AATD-associated liver disease.
• Beam Therapeutics is exploring BEAM-302, a liver-targeting base editing therapy, while Wave Life Sciences, AIRNA, and Korro Bio are advancing RNA-editing oligonucleotides for AATD.
• With multiple investigational treatments showing promise, augmentation therapy could become obsolete within the next decade, potentially transforming AATD treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath